Resident
Truong, Jennifer, PharmD
Residency Program
BC Cancer
Project Title
Utilization and Toxicity Patterns of 2-Weekly (Q2W) versus 4-Weekly (Q4W) Nivolumab for Treatment of Adjuvant and Metastatic Melanoma at BC Cancer
Investigators
Yeung, Shirley (BSc(Pharm), ACPR, MSc), Kletas, Victoria (BSc(Pharm), ACPR, MSc); de Lemos, Mario (PharmD, MSc(Oncol)); Schaff, Kimberly (RPhT); Nakashima, Lynne (BSc(Pharm), PharmD)
Abstract
Nivolumab is associated with immune-related adverse events (IrAEs). Original dosing for melanoma was 3 mg/kg (maximum 240 mg) Q2W. Based on pharmacokinetic/pharmacodynamic simulation studies depicting similar efficacy and toxicity to original dosing, extended interval dosing of 6 mg/kg (maximum 480 mg) Q4W was introduced. The exact mechanisms of IrAEs are unclear and their incidence and onset have not been described in real-world practice for the higher doses used in extended dosing. This uncertainty may defer physicians from choosing the extended dosing interval option. The purpose of this study is to compare the safety profile between Q2W and Q4W dosing.
